Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$58.93 - $95.25
Previous CloseN/A
Volume821.68K
Average Volume (3M)5.02M
Market Cap
$40.65B
Enterprise Value$40.50B
Total Cash (Recent Filing)$321.20M
Total Debt (Recent Filing)$129.30M
Price to Earnings (P/E)28.3
Beta0.92
Next Earnings
Apr 23, 2025EPS Estimate
0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.59
Shares Outstanding585,755,500
10 Day Avg. Volume5,604,855
30 Day Avg. Volume5,024,328
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.62
Price to Cash Flow (P/CF)-81.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.37
Enterprise Value/Ebitda22.33
Forecast
1Y Price Target
$79.07Price Target Upside5.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceEdwards delivered a solid all-around quarter and projected confidence in the 2025 framework despite macro and M&A moving parts.
Market PositionEdwards is now the only company with both repair and replacement devices in the treatment of both mitral and tricuspid valves.
Product InnovationThe CE Mark approval of SAPIEN M3 strengthens Edwards Lifesciences’ TMTT unit, attracting more investor attention and serving as a crucial growth driver.
Bears Say
Capacity ConstraintsConcerns exist that capacity constraints could limit the potential upside for growth between Edwards Lifesciences' U.S. TAVR and TMTT segments.
Pricing EnvironmentConcerns exist about the pricing environment for TAVR, as some competitors have been pricing at sizable discounts.
Sales GrowthLatest survey results show a deceleration of Edwards Lifesciences' U.S. TAVR sales growth on an annual basis, which aligns with a more cautious outlook.
---
Ownership Overview
0.94% Insiders
23.18% Mutual Funds
1.37% Other Institutional Investors
49.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $58.93 and its highest was $95.25 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $40.65B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Apr 23, 2025 which is 2 days ago.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 23, 2025. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.596 by $0.044.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.6.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 585,755,500 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.64 in its last earnings report, beating expectations of $0.596. Following the earnings report the stock price went up 6.628%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
---
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$79.07 (5.24% Upside)
$79.07 (5.24% Upside)
Blogger Sentiment
Bullish
EW Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $873.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.07%
12-Months-Change
Fundamentals
Return on Equity
17.17%
Trailing 12-Months
Asset Growth
39.43%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation (EW) is a global leader in the science of heart valves and hemodynamic monitoring. The company specializes in developing innovative medical devices and technologies designed to treat structural heart disease and critically ill patients. Its core products include transcatheter heart valves, surgical heart valves, and critical care monitoring systems. Edwards Lifesciences operates primarily in the healthcare sector, with a focus on cardiovascular care and enhancing patient outcomes through pioneering solutions.
---
EW Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and strategic advancements, such as significant revenue growth and successful product approvals. However, challenges in the Japan market and anticipated financial impacts from tariffs and acquisitions present potential hurdles.Read More>---
EW Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
18.04% Surgical Structural Heart
6.47% Transcatheter Mitral and Tricuspid Therapies
---
EW Stock 12 Month Forecast
Average Price Target
$79.07
▲(5.24% Upside)
Technical Analysis
Best Analysts Covering EW
1 Year
1 Year Success Rate
21/31 ratings generated profit
1 Year Average Return
+10.63%
reiterated a buy rating 5 months ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 67.74% of your transactions generating a profit, with an average return of +10.63% per trade.
---